Single answer
Is Adaptive Biotechnologies (ADPT) a buy or sell?
4starter turns market data into one clear verdict you can act on.
Create a free account to save tickers and track your signals.
Log in to turn on watchlist alerts.
What is the conclusion?
Right now our advanced algorithms say:
$1 invested is now $1.23 or 23.21%
(In 34 weeks 4 days 23 hours 37 minutes and 6 seconds .)
Do analysts agree?
We compare consensus targets with today's price.
Consensus target for Adaptive Biotechnologies Corporation is $20.33, which is $3.92 (23.89%) above the current price today's price.
Low target: $20.00 | High target: $21.00
Company snapshot
A quick overview of the business and its public profile.
Adaptive Biotechnologies Corporation a commercialstage company develops an immune medicine platform for the diagnosis and treatment of various diseases The company offers immunoSEQ a platform and core immunosequencing product that is used to answer translational research questions as well as to discover new prognostic and diagnostic signals and TDetect COVID for the confirmation of past COVID19 infection It also provides clonoSEQ a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma B cell acute lymphoblastic leukemia and chronic lymphocytic leukemia as well as available as a CLIAvalidated laboratory developed test for patients with other lymphoid cancers and immunoSEQ TMAP COVID for vaccine developers and researchers to measure the Tcell immune response to vaccines In addition the company offers a pipeline of clinical products and services that are used for the diagnosing monitoring and treatment of diseases such as cancer autoimmune conditions and infectious diseases It serves the life sciences research clinical diagnostics and drug discovery applications Adaptive Biotechnologies Corporation has strategic collaborations with Genentech Inc for the development manufacture and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011 Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle Washington
Website: https://www.adaptivebiotech.com
Rates and inflation backdrop
US inflation for September 2025 was 0.31%. Over the last 12 months, inflation is 3.02%. The 10-year yield is 4.12 and is down -0.1000 over the last 30 days.
Inflation sensitivity
Debt ratio: 0.44. Cash flow to debt ratio: -0.28. Net profit margin: -31.50%. Inflation risk score: high (0.85/1).
Dividend history check
We cannot find any recorded dividends paid in our systems.
Trading liquidity
Yes, the average daily trading liquidity for Adaptive Biotechnologies is $32.7M. You should therefore be able to get in and out of your positions relatively fast.
10-year return check
We cannot find data for Adaptive Biotechnologies 10 years ago, but if you had invested on 2019-06-27 when the price was $40.30, you would have made a loss of $23.88 per share or 59.26%.
Why this answer
We combine price momentum, volatility, and trend signals to simplify the decision to one word.
Signal engine scans price, trend, and momentum indicators.
Targets and sentiment are checked against the live quote.
We keep the output simple: buy, sell, or hold.
Analyst consensus
How Wall Street targets compare to today's price.